Insider Ledger
PLYX insider buying and SEC filings, explained
Polaryx Therapeutics, Inc. · CIK 2075320
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- WY
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| May 27, 2026 | Other purchase | Alex Keun Mo Yang (CEO and Director) bought 88,453 Common Stock indirectly at $4.07 ($360K) in a private placement. Indirect holdings up <1% to 24,233,249 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 1 other reporting owner. | SEC filing Filed May 28, 2026 |
| Feb 18, 2026 | Purchase (code P) | G. Michael Landis (CFO and Director) bought 2,867 shares at $2.79 ($8K), reported as a purchase (code P). Holdings up 1% to 228,225 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow PLYX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.